Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Brain Behav Immun. 2021 Mar 15;95:178–189. doi: 10.1016/j.bbi.2021.03.015

Table 2.

Longitudinal sample characteristics.

Total Sample N = 74
PiB− N = 47
PiB+ N = 27
M, SD or % (N) M, SD or % (N) M, SD or % (N)
Age, y 85.34 ± 2.97 V 85.28 ± 2.62 85.44 ± 3.56

Sex (Female) 43.2% (32) 38.3% (18) 51.9% (14)

Education, y 14.99 ± 2.70 15.2 ± 2.78 14.56 ± 2.56

ApoE ε4+ 17.6% (13) 8.5% (4) 33.3% (9)

Heart Disease 13.5% (10) 14.9% (7) 11.1% (3)

Diabetes 4.1% (3) 4.3% (2) 3.7% (1)

Anti-hypertensive medication, % yes 66.2% (49) 66% (31) 66.7% (18)

CES-D 3.62 ± 4.27 2.96 ± 4.38 4.78 ± 3.9

sCD14 1381.1 ± 277.59 1360.86 ± 298.6 1416.32 ± 237.79

CRP 1.83 ± 1.79 1.8 ± 1.56 1.97 ± 2.17

sTNFr1 1278.34 ± 363.31 1317 ± 374.37 1211.06 ± 339.46

sTNFr2 6231.58 ± 1623.94 6388.65 ± 1815. 94 5958.18 ± 1203.3

IL-6 2.67 ± 1.74 2.70 ± 1.62 2.60 ± 1.96

Duration blood draw to PET, weeks 82.12 ± 28.10 84.78 ± 33.21 77.48 ± 14.19

Duration, consecutive scans (weeks) 96.59 ± 26.89 90.92 ± 23.12 106.48 ± 30.33

Abbreviations: APOE= apolipoprotein; sCD14 = soluble cluster of differentiation 14; CES-D = Center for Epidemiological Studies Depression; CRP = C-reactive protein; IL-6 = Interleukin-6; MMSE = Mini Mental Status Exam; sTNFr1 = soluble Tumor Necrosis Factor receptor; sTNFr2 = soluble Tumor Necrosis Factor receptor 2